Sign In
Buy SPRY
$8.75
-0.150 (-1.69%)
At Close: Jun 03, 2026
ARS Pharmaceuticals, Inc. (SPRY) Q1 2025 Earnings Call Transcript
01:32pm, Wednesday, 14'th May 2025
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q1 2025 Earnings Conference Call May 14, 2025 8:30 AM ET Company Participants Justin Chakma - CBO Richard Lowenthal - Co-Founder, President and CEO Eric Karas
ARS Pharmaceuticals, Inc. (SPRY) Reports Q1 Loss, Lags Revenue Estimates
09:16am, Wednesday, 14'th May 2025
ARS Pharmaceuticals, Inc. (SPRY) came out with a quarterly loss of $0.35 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.11 per share a year ago.
$7.8 million in total neffy U.S. net product revenue in first quarter of 2025 neffy 1 mg available nationwide for children aged four and older and co-promotion agreement with ALK-Abelló Inc. increase
The availability of neffy 1 mg extends protection to younger, school-aged children—who make up nearly 23% of people needing epinephrine Visit neffy.com for savings and support programs and pay as li
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2025 Financial Results
08:00am, Monday, 05'th May 2025
SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves f
Agreement builds on landmark licensing deal between ARS Pharma and ALK-Abelló A/S, which provided ARS Pharma with $145 million upfront and ALK with commercialization rights to neffy in Canada, United
ARS Pharmaceuticals Has A Blockbuster Candidate
06:51am, Wednesday, 30'th Apr 2025
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and i
ARS Pharmaceuticals: Surging On Solid Earnings - But Real Challenges Await
03:31pm, Thursday, 20'th Mar 2025
ARS Pharmaceuticals, Inc.'s stock surged 25% today after strong Q4 and full-year 2024 earnings, driven by the needle-free epinephrine treatment, neffy, which has promising market potential. Neffy's co
ARS Pharmaceuticals, Inc. (SPRY) Q4 2024 Earnings Conference Call Transcript
01:28pm, Thursday, 20'th Mar 2025
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY ) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Justin Chakma - Chief Business Officer Richard Lowenthal - Co-Founder, Presiden
ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move. Here's Why.
11:15am, Thursday, 20'th Mar 2025
Shares of ARS Pharmaceuticals bounded higher Thursday after the company reported an unexpected fourth-quarter metrics. The post ARS Pharma Retakes Its 50-Day Line In Bullish Post-Earnings Move.
ARS Pharmaceuticals, Inc. (SPRY) Q4 Earnings and Revenues Beat Estimates
09:25am, Thursday, 20'th Mar 2025
ARS Pharmaceuticals, Inc. (SPRY) came out with quarterly earnings of $0.52 per share, beating the Zacks Consensus Estimate of a loss of $0.04 per share. This compares to loss of $0.07 per share a year
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates
07:00am, Thursday, 20'th Mar 2025
$7.3 million in total neffy ® (epinephrine nasal spray) U.S. net product revenue in 2024 since launch in late September 2024
neffy 1 mg is the first and only needle-free epinephrine treatment approved for younger children
Company to Host Conference Call on March 20 at 8:30 a.m. ET SAN DIEGO, March 03, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering
Approximately five months after launch, the inclusion of neffy on these three additional formularies has expanded access to half of all patients and caregivers managing Type 1 allergic reactions, brin
